Skip to main content
. 2022 Jan 7;39:100928. doi: 10.1016/j.gore.2022.100928

Table 5b.

Impact of COVID-19 pandemic on administration of neo-adjuvant chemotherapy in patients with ovarian cancer.

Variable Total
N = 96
Pre-COVID-19
N = 48
COVID-19
N = 48
P value
Patients who received neo-adjuvant chemotherapy 20 (20.8) 11 (22.9) 9 (18.8) 0.615
Number of cycles of neo-adjuvant chemotherapy 3.5 (1.0) 3.8 (1.2) 3.1 (0.6) 0.111